Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
[HTML][HTML] Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima… - Nature medicine, 2023 - nature.com
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
T Powles, ZJ Assaf, N Davarpanah, R Banchereau… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna… - Clinical Cancer …, 2021 - AACR
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer
METHODS This guideline is based on the previous colon cancer parameter published in
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …
[HTML][HTML] Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
H Zhou, L Zhu, J Song, G Wang, P Li, W Li, P Luo… - Molecular cancer, 2022 - Springer
Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …
cancer. However, existing biomarkers do not reliably predict treatment response across …
[HTML][HTML] Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …